

## Product datasheet for **TL313116V**

### Tissue Factor (F3) Human shRNA Lentiviral Particle (Locus ID 2152)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Tissue Factor (F3) Human shRNA Lentiviral Particle (Locus ID 2152)
Locus ID:	2152
Synonyms:	CD142; TF; TFA
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	F3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_001178096</a> , <a href="#">NM_001993</a> , <a href="#">NM_001993.1</a> , <a href="#">NM_001993.2</a> , <a href="#">NM_001993.3</a> , <a href="#">NM_001993.4</a> , <a href="#">NM_001178096.1</a> , <a href="#">BC011029</a> , <a href="#">BC011029.1</a> , <a href="#">BM769013</a> , <a href="#">BM981095</a> , <a href="#">NM_001993.5</a>
UniProt ID:	<a href="#">P13726</a>
Summary:	<p>This gene encodes coagulation factor III which is a cell surface glycoprotein. This factor enables cells to initiate the blood coagulation cascades, and it functions as the high-affinity receptor for the coagulation factor VII. The resulting complex provides a catalytic event that is responsible for initiation of the coagulation protease cascades by specific limited proteolysis. Unlike the other cofactors of these protease cascades, which circulate as nonfunctional precursors, this factor is a potent initiator that is fully functional when expressed on cell surfaces, for example, on monocytes. There are 3 distinct domains of this factor: extracellular, transmembrane, and cytoplasmic. Platelets and monocytes have been shown to express this coagulation factor under procoagulatory and proinflammatory stimuli, and a major role in HIV-associated coagulopathy has been described. Platelet-dependent monocyte expression of coagulation factor III has been described to be associated with Coronavirus Disease 2019 (COVID-19) severity and mortality. This protein is the only one in the coagulation pathway for which a congenital deficiency has not been described. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Aug 2020]</p>
shRNA Design:	<p>These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a>. If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a>.</p>



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).